4-Aminoethylamino-emodin - a novel potent inhibitor of GSK-3β - acts as an insulin-sensitizer avoiding downstream effects of activated β-catenin

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 A, 2010, Pages 1276-1293

  Gebhardt, Rolf ^a   Lerche, Katja S ^a   Götschel, Frank ^b   Günther, Robert ^a   Kolander, Jens ^a   Teich, Lars ^a   Zellmer, Sebastian ^a   Hofmann, Hans Jörg ^a   Eger, Kurt ^a   Hecht, Andreas ^b   Gaunitz, Frank ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

catenin; 4 aminoethyl aminoemodin; Glycogen synthase kinase 3 ; Inhibition; Insulin sensitizer; Protein kinase inhibitor; Signalling

Indexed keywords

4 AMINOETHYLAMINO EMODIN; 4-AMINOETHYLAMINO-EMODIN; AXIN2 PROTEIN, MOUSE; BETA CATENIN; CASEIN KINASE II; CYTOSKELETON PROTEIN; DRUG DERIVATIVE; EMODIN; FATTY ACID; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INSULIN; PROTEIN KINASE INHIBITOR; T CELL FACTOR PROTEIN; AXIN;

ANIMAL; ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL CULTURE; CELL DEATH; CELL SURVIVAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IC 50; LIVER CELL; METABOLISM; MOUSE; PROTEIN STABILITY; RAT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; IC50;

ANIMALS; BETA CATENIN; CASEIN KINASE II; CELL DEATH; CELL SURVIVAL; CELLS, CULTURED; CYTOSKELETAL PROTEINS; EMODIN; FATTY ACIDS; GLYCOGEN; GLYCOGEN SYNTHASE KINASE 3; HEPATOCYTES; HUMANS; INHIBITORY CONCENTRATION 50; INSULIN; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STABILITY; RATS; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; AXIN PROTEIN;

EID: 77955155901     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00701.x     Document Type: Article

References (83)

1. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT - a major therapeutic target. Biochem. Biophys. Acta. 2004, 1697:3-16.
2. Dong LQ, Feng L. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. Am J Physiol Endocrinol Metab. 2005, 289:E187-96.
3. McManus EJ, Sakamoto K, Armit LJ. Role that phosphorylation of GSK-3 plays in insulin and Wnt signalling defined by knockin analysis. EMBO J. 2005, 24:1571-83.
4. Parker PJ, Caudwell FB, Cohen P. Glycogen synthase from rabbit skeletal muscle; effect of insulin on the state of phosphorylation of the seven phosphoser ine residues in vivo. Eur J Biochem. 1983, 130:227-34.
5. Furnsinn C, Noe C, Herdlicka R. More marked stimlation by lithium than insulin of the glycogenic pathway in rat skeletal muscle. Am J Physiol. 1997, 273:E514-20.
6. Seo YH, Jung HJ, Shin HT. Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation. Aging Cell. 2008, 7:894-907.
7. Lochhead PA, Coghlan M, Rice SQ. Inhibition of GSK-3 selectively reduces glucose-6-phosphatase and phosphoenolypyruvate carboxykinase gene expression. Diabetes. 2001, 50:937-46.
8. Kim KH, Song MJ, Yoo EJ. Regulatory role of glycogen synthase kinase 3 for transcriptional activity of ADD1/SREBP1c. J Biol Chem. 2004, 279:51999-2006.
9. Bullock WH, Magnuson SR, Choi S. Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. J Curr Top Med Chem. 2002, 2:915-38.
10. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003, 116:1175-86.
11. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nature Rev Drug Disc. 2004, 3:479-87.
12. Meijer L, Flajolet M, Greengard P. Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci. 2004, 25:471-80.
13. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci. 2007, 64:1930-44.
14. Bhat RV, Haeberlein SLB, Avila J. Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurosci. 2004, 89:1313-7.
15. Selenica ML, Jensen HS, Larsen AK. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Brit J Pharmacol. 2007, 152:959-79.
16. Phiel CJ, Wilson CA, Lee VM. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature. 2003, 423:435-9.
17. De Strooper B, Woodgett J. Alzheimer's disease: mental plaque removal. Nature. 2003, 423:392-3.
18. Muyllaert D, Kremer A, Jaworski T. Glycogen synthase kinase-3 beta, or a link between amyloid and tau pathology. Genes Brain Behav. 2008, 7:57-66.
19. Frame S, Zheleva D. Targeting glycogen synthase kinase-3 in insulin signalling. Expert Opin Ther Targets. 2006, 10:429-44.
20. Gould TD. Targeting glycogen synthase kinase-3 as an approach to develop novel mood-stabilising medications. Expert Opin Ther Targets. 2006, 10:377-92.
21. Murray JT, Cambell DG, Morrice N. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J. 2004, 384:477-88.
22. Bain J, Plater L, Elliott M. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007, 408:297-315.
23. Kulkarni NH, Onyia JE, Zeng QQ. Orally bioavailable GSK-3 alpha/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J Bone Min Res. 2006, 21:910-20.
24. Coghlan MP, Culbert AA, Cross DA. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000, 7:793-803.
25. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Design. 2004, 10:1105-37.
26. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127:469-80.
27. Gebhardt R, Baldysiak-Figiel A, Krügel V. Hepatocellular expression of glutamine synthetase: an indicator of morphogen actions as master regulators of zonation in adult liver. Prog Histochem Cytochem. 2007, 41:201-66.
28. Seidensticker MJ, Behrens. Biochemical interactions in the wnt pathway. J Biochim Biophys Acta. 2000, 1495:168-82.
29. Buillons LC, Levine AJ. The role of beta-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol. 1998, 10:81-7.
30. Cadoret A, Ovejero C, Saadi-Kheddouci S. Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. Cancer Res. 2001, 61:3245-49.
31. Thomas GM, Frame S, Goedert M. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and beta-catenin. FEBS Lett. 1999, 458:247-51.
32. Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr Drug Targets. 2006, 7:1421-34.
33. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol. 1998, 14:59-88.
34. Teich L, Daub KS, Krügel V. Synthesis and biological evaluation of new derivatives of emodin. Bio Med Chem. 2004, 12:5961-71.
35. Yim H, Lee YH, Lee CH. Emodin, an anthraquinone derivative isolated from the rhizomes of Eheum palmatum, selectively inhibits the activity of casein kinase II as a competitive inhibitor. Planta Med. 1999, 65:9-13.
36. Battistutta R, Sarno S, De Mliner E. The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem. 2000, 275:29618-22.
37. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem. 2000, 275:32475-81.
38. Schlupper D, Giesa S, Gebhardt R. Influence of biotransformation of luteolin, luteolin 7-O-glucoside, 3′,4′-dihydroxyflavone and apigenin by cultured rat hepatocytes on antioxidative capacity and inhibition of EGF receptor tyrosine kinase activity. Planta Med. 2006, 72:596-603.
39. Gebhardt R, Hengstler J, Müller D. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug developtment, standard operation procedures. Drug Metab. Rev. 2003, 35:145-213.
40. Burger HJ, Gebhardt R, Mayer C. Different capacities for amino acid transport in periportal and perivenous hepatocytes isolated by digitonin/collagenase perfusion. Hepatology. 1989, 9:22-8.
41. Gebhardt R. Antioxidative and protective properties of extracts from leaves of the artichoke (Cynara scolymus L.) against hydroperoxide-induced oxidative stress in cultured rat hepatocytes. Toxicol Appl Pharmacol. 1997, 144:279-86.
42. Gebhardt R, Beck H. Differential inhibitory effects of garlic-derived organosulfur compounds on cholesterol biosynthesis in primary rat hepatocyte cultures. Lipids. 1996, 31:1269-76.
43. Fahrner J, Labruyere WT, Gaunitz C. Identification and functional characterization of regulatory elements of the glutamine synthetase gene from rat liver. Eur J Biochem. 1993, 213:1067-73.
44. Kispert A, Vainio S, McMahon AP. Wnt-4 is a mesenchymal signal for epithelial transformation of metanephric mesenchyme in the developing kidney. Development. 1998, 125:4225-34.
45. Aoki M, Hecht A, Kruse U. Nuclear endpoint of Wnt signaling: neoplastic transformation induced by transactivating lymphoid-enhancing factor 1. Proc Natl Acad Sci USA. 1996, 96:139-44.
46. Snyder EY, Deitcher DL, Walsh C. Multipotent neural cell lines can engraft and participate in development of Mouse cerebellum. Cell. 1992, 68:33-51.
47. Gaunitz F, Heise K. HTS compatible assay for antioxidative agents using primary cultured hepatocytes. Assay Drug Dev Technol. 2003, 1:469-77.
48. Cross DE, Watt PW, Shaw M. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett. 1997, 406:211-5.
49. Gebhardt R, Williams GM. Amino acid transport in established adult rat liver epithelial cell lines. Cell Biol Toxicol. 1986, 2:9-20.
50. Bradford MM. A rapid and sensitive method fort he quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-53.
51. Pfleiderer G. Glykogen. Bestimmung als D-Glucose mit Hexokinase, Pyruvatkinase und Lactat-Dehydrogenase. Methoden der enzymatischen analyse 1962, 59-62. Bergmeyer U. In, editor, Weinheim, Verlag Chemie, pp
52. Haupt W, Gaunitz F, Gebhardt R. Post-transcriptional inhibition of glutamine synthetase induction in rat liver epithelial cells exerted by conditioned medium from rat hepatocytes. Life Sci. 2000, 67:3191-8.
53. Nagata Y, Hikada Y, Ishida F. Effect of simvastatin /MK-733) on the regulation of cholesterol synthesis in HepG2 cells. Biochem Pharmacol. 1990, 40:843-50.
54. Aberle H, Schwartz H, Hoschuetzky H. Single amino acid substitutions in proteins of the armadillo gene family abolish their binding to alpha-catenin. J Biol Chem. 1996, 271:1520-6.
55. Hecht A, Litterst CM, Huber O. Functional characterization of multiple transactivating elements in beta-catenin, some of thich interact with the TATA-binding protein in vitro. J Biol Chem. 1999, 274:18017-25.
56. Austinat M, Dunsch R, Wittekind C. Correlation between beta-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma. Mol Cancer. 2008, 7:21.
57. Gaunitz F, Papke M. Gene transfer and expression. Methods Mol Biol. 1998, 107:361-70.
58. Bhat R, Xue Y, Berg S. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitior AR-A014418. J Biol Chem. 2003, 278:45937-45.
59. Dewar MJS, Zoebisch EG, Healy EF. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc. 1985, 107:3902-9.
60. Morris GM, Goodsell DS, Halliday RS. Automated docking using a Lamarckian genetic algorithm and empirical bindung free energy function. J Comput Chem. 1998, 19:1639-62.
61. Jordan CT. The leukemic stem cell. Best Pract. Res. Clin. Haematol. 2007, 20:13-8.
62. Staal FJ, Noort M, Strous GJ. Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep. 2002, 3:63-8.
63. van Noort M, Meeldijk J, van der Zee R. Wnt signaling controls the phosphorylation status of beta-catenin. J Biol Chem. 2002, 277:17901-5.
64. Hirsch C, Campano LM, Wöhrle S. Canonical Wnt signaling transiently stimulates proliferation and enhances neurogenesis in neonatal neural progenitor cultures. Exp Cell Res. 2007, 313:572-87.
65. Aberle H, Bauer A, Stappert J. Beta-catenin is a target for the ubiquitin-proteasome pathway. EMBO J. 1997, 16:3797-804.
66. Jho EH, Zhang T, Domon C. Wnt/beta-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol. 2002, 22:1172-83.
67. Leung JY, Kolligs FT, Wu R. Activation of AXIN2 expression by beta-catenin-T cell factor. A feedback repressor pathway regulating Wnt signaling. J Biol Chem. 2002, 277:21657-65.
68. Lustig B, Jerchow B, Sachs M. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. J Mol Cell Biol. 2002, 22:1184-93.
69. Loeppen S, Schneider D, Gaunitz F. Overexpression of glutamine synthetase is associated with beta-catenin-mutations in mouse liver tumors during promotion of hepatocarcinogenesis by phenobarbital. Cancer Res. 2002, 62:5685-8.
70. Kruithof-de Julio M, Labruyère WT, Ruijter JM. The RL-ET-14 cell line mediates expression of glutamine synthetase through the upstream enhancer/promoter region. J Hepatol. 2005, 43:126-31.
71. Hers I, Tavare JM, Denton RM. The protein kinase C inhibitors bisindolylmaleimide I (GF 109203x) and IX (Ro 31-8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett. 1999, 460:433-6.
72. Kuo GH, Prouty C, DeAngelis A. Synthesis and discovery of macrocyclic polyoxygenated Bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3 beta inhibitors. Med Chem. 2002, 46:4021-31.
73. Kunick K, Lauenroth K, Leost M. 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004, 14:413-6.
74. Logé C, Testard A, Thiéry V. Novel 9-oxo-thiazolo [5,4-f] quinazoline-2-carbonitrile derivatives as dual cyclin-dependent kinase 1 (CDK-1)/glycogen synthase kinase-3 (GSK-3) inhibitors: synthesis, biological evaluation and molecular modeling studies. Eur J Med Chem. 2008, 43:1469-77. 10.1016/j.ejmech.2007.09.020, doi
75. Bertrand JA, Thieffine S, Vulpetti A. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors. J Med Biol. 2003, 333:393-407.
76. Shin D, Lee SC, Heo YS. Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3beta. Bioorg Med Chem Lett. 2007, 17:5686-9.
77. Xiao J, Guo Z, Guo Y. Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses. Prot Eng Des Sel. 2006, 19:47-54.
78. Dessalew N, Bharatam PV. Identification of potential glycogen kinase-3 inhibitors by structure based virtual screening. Biophys Chem. 2007, 128:165-75.
79. Beurel E, Jope RS. The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol. 2006, 79:173-89.
80. Götschel F, Kern C, Lang S. Inhibition of GSK3 differentially modulates NF-kappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis. Exp Cell Res. 2008, 314:1351-66.
81. Lefebvre V, Goffin I, Buc-Calderon P. Fructose metabolism and cell survival in freshly isolated rat hepatocytes incubated under hypoxic conditions: proposals for potential clinical use. Hepatology. 1994, 20:1567-76.
82. Lochhead PA, Salt IP, Walker KS. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes. 2000, 49:896-903.
83. Martinez A. Preclinical efficacy on GSK-3 inhibitors: towards a future generation of powerful drugs. Med Res Rev. 2008, 28:773-96. 10.1002/med, doi